Ozanimod (Zeposia®) for Ulcerative Colitis. HTA ID: 22002

Assessment Status Rapid Review Complete
HTA ID 22002
Drug Ozanimod
Brand Zeposia®
Indication For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Assessment Process
Rapid review commissioned 10/01/2022
Rapid review completed 01/02/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ozanimod compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations, December 2022.